We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.18%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.6B
AUM Growth
+$224M
Cap. Flow
-$30.2M
Cap. Flow %
-0.17%
Top 10 Hldgs %
87.48%
Holding
123
New
5
Increased
24
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$32.5M
2
ASND icon
Ascendis Pharma A/S
ASND
+$29.3M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.6M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$19.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$16.2M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$63.5M
2
LEGN icon
Legend Biotech
LEGN
+$48.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$25.3M
4
MRUS
Merus
MRUS
+$21.8M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.64M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
101
Cabaletta Bio
CABA
$435M
$702K ﹤0.01%
662,063
– –
CYPH
102
Cypherpunk Technologies Inc
CYPH
$64.4M
$644K ﹤0.01%
55,971
– –
FHTX icon
103
Foghorn Therapeutics
FHTX
$279M
$612K ﹤0.01%
45,027
– –
BNR
104
Burning Rock Biotech
BNR
$95.5M
$609K ﹤0.01%
20,913
– –
TARA icon
105
Protara Therapeutics
TARA
$216M
$585K ﹤0.01%
199,671
– –
KZR
106
DELISTED
Kezar Life Sciences
KZR
$512K ﹤0.01%
6,195
-7,773
-56% -$686K
INZY
107
DELISTED
Inozyme Pharma
INZY
$510K ﹤0.01%
106,999
– –
SERA icon
108
Sera Prognostics
SERA
$82.6M
$331K ﹤0.01%
201,562
– –
VINC
109
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$319K ﹤0.01%
12,069
– –
BLCM
110
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$296K ﹤0.01%
249,123
– –
PASG icon
111
Passage Bio
PASG
$14.6M
$276K ﹤0.01%
5,858
– –
SRZNW icon
112
Surrozen Inc Warrant
SRZNW
$36.6K
$159K ﹤0.01%
833,333
– –
LOGC
113
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$158K ﹤0.01%
451,478
– –
NEXI
114
DELISTED
NexImmune, Inc. Common Stock
NEXI
$32K ﹤0.01%
800
-10,965
-93% -$679K
AXSM icon
115
Axsome Therapeutics
AXSM
$11.8B
– –
-610,970
Closed -$25.3M
KURA icon
116
Kura Oncology
KURA
$816M
– –
-274,458
Closed -$4.41M
NBIX icon
117
Neurocrine Biosciences
NBIX
$18.3B
– –
-676,975
Closed -$63.5M
NVAX icon
118
Novavax
NVAX
$1.22B
– –
-48,168
Closed -$3.55M
SRPT icon
119
Sarepta Therapeutics
SRPT
$1.66B
– –
-123,456
Closed -$9.64M
OYST
120
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
– –
-61,424
Closed -$715K
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Baker Bros. Advisors held 123 positions worth $17.6B, up 1.3% from $17.4B the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Baker Bros. Advisors's Q2 2022 filing shows 5 new, 24 increased, 7 reduced and 6 closed positions. Its largest new stake was Vor Biopharma: 56,938 shares worth $5.66M. The largest sale was Neurocrine Biosciences, an estimated $63.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2022 buy was Vor Biopharma: 56,938 shares worth $5.66M.
  • Baker Bros. Advisors added most to Replimune Group in Q2 2022, an estimated $32.5M increase.
  • Baker Bros. Advisors's biggest Q2 2022 reduction was Legend Biotech, cutting an estimated $48.7M.
  • Baker Bros. Advisors fully exited Neurocrine Biosciences in Q2 2022, selling an estimated $63.5M.
  • Baker Bros. Advisors's ten largest holdings make up 87% of its $17.6B portfolio in Q2 2022.
  • Baker Bros. Advisors opened 5 new positions and closed 6 in Q2 2022.
  • Baker Bros. Advisors's portfolio value rose 1.3% quarter-over-quarter to $17.6B.

Based on Baker Bros. Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.